Research
Our mains research interests
1. Molecular classification,
and predictive modeling in cancer
We have a strong track record in conducting large scale molecular profiling studies in cancer to improve our understanding of disease pathogenesis, develop clinico-genomic guidelines for patient classification and risk stratification, and identify predictive biomarkers of therapeutic response. By integrating multiple data modalities from patient samples, we perform detailed genotype-phenotype analysis and develop statistical models to predict clinical outcomes and therapeutic responses. We currently focus on (i) the molecular subtypes of myeloid malignancies, (ii) the integration of multi-modal data into prognostic models, and (iii) analyzing molecular dynamics under treatments using non invasive technologies (cell free DNA assays).
2. Clonal hematopoiesis in cancer
We study the acquisition of somatic mutations in blood cells, known as clonal hematopoiesis. While clonal hematopoiesis is a common age-related condition, our research focuses on its significance in patients with cancer and in survivors from cancer. Specifically, we aim to understand the associations between anticancer therapies and clonal hematopoiesis, as well as its evolutionary dynamics. Using longitudinal patient samples and single-cell technologies, we track these evolutionary changes over time. Additionally, we are also particularly interested in the systemic effects of clonal hematopoiesis, including its influence on the tumor microenvironment and its role in driving tumor evolution.
We have established local and international collaborations to conduct large scale clinico-genomic characterizations of therapy-related malignancies, aiming to improve precision diagnostics and interception strategies. By utilizing whole genome sequencing, we explore the broader mutational landscape of these malignancies. Additionally, we are co-leading the Clonal Interception prospective study at Gustave Roussy, a pioneering scientific program designed to anticipate the risk of leukemia induced by prior anticancer treatments. In Clonal Interception, we monitor patients at risk of developing a secondary myeloid neoplasm over time. We aim to identify predictive biomarkers of transformation, which will contribute to the development of strategies to prevent the onset of these malignancies.